Endocrine Abstracts

Background and aims: Proper assessment of long-term safety of newer antidiabetic agents (ADAs) is of prime importance as diabetes is a chronic disease requiring life-long management. The purpose of this analysis was to assess the safety of vildagliptin as monotherapy or as an add-on therapy to already existing ADAs (vildagliptin group) compared to non-vildagliptin group.Materials and methods: Nine hundred and eighty-three patients in vildagliptin group a...